← Leaderboards
Alexey V. Danilov
Beckman Research Institute/City Of Hope
$3,278,847
Attributed
$6,157,737
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,157,737 · 3
By mechanism
UM1$3,196,988 · 1
R01$2,960,749 · 2
Top collaborators
- A. Dimitrios Colevas2 shared
- Primo N Lara2 shared
- Heinz Josef Lenz2 shared
- Lili Wang1 shared
- Zheng Xia1 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Chun-Wei David Chen$8,071,175
Others in their field
Other Emerging Leaders on “Tumor Microenvironment”
- Crystal Mackall · Children'S Hosp Of Philadelphia$14,123,910
- Jennifer M Munson · Virginia Polytechnic Inst And St Univ$9,002,754
- Sana D Karam · University Of Colorado Denver$8,565,041
- Nicholas Arpaia · Columbia Univ New York Morningside$6,003,313
- Cara L Haymaker · University Of Tx Md Anderson Can Ctr$5,881,654
- Gheath Al-Atrash · University Of Tx Md Anderson Can Ctr$5,881,654
Research focus
Tumor MicroenvironmentTumorNeoplastic CellClinical TrialsPre-ClinicalSignal TransductionNovel StrategiesMutationPathogenesisIn VitroChronic Lymphocytic LeukemiaMouse ModelGenetic TranscriptionIn VivoCellsGenesDiagnosisFailureB-LymphocytesChemotherapyImmuneImmunoregulationBcl2 GeneCell Physiology
Grant awards (8)
Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN$1,903,401
UM1 · FY2025 · CA · contact PI
Attacking the Tumor Cell-Immune Milieu Interface to Overcome Richter's Transformation$721,723
R01 · FY2025 · CA
Overcoming ibrutinib resistance in mantle cell lymphoma$450,309
R01 · FY2025 · CA · contact PI
Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN$1,293,587
UM1 · FY2024 · CA · contact PI
Overcoming ibrutinib resistance in mantle cell lymphoma$427,795
R01 · FY2024 · CA · contact PI
Overcoming ibrutinib resistance in mantle cell lymphoma$441,302
R01 · FY2023 · CA · contact PI
Overcoming ibrutinib resistance in mantle cell lymphoma$450,951
R01 · FY2022 · CA · contact PI
Overcoming ibrutinib resistance in mantle cell lymphoma$468,669
R01 · FY2021 · CA · contact PI